艾立布林显著延长HER2阴性乳腺癌总生存期

近日，一项发表在《eClinicalMedicine》的文章报告了艾立布林用于一线或二线HER2-MBC的III期临床试验结果。与标准一线化疗S-1相比，艾立布林显著延长患者总生存期，两组患者首次临床恶化时间相似，显示出艾立布林作为HER2-MBC一线/二线治疗选择的潜力。CCMTV将其编译成文，以飨读者。

https://mp.weixin.qq.com/s?__biz=Mzg2NTY5NzA2MQ==&mid=2247611774&idx=1&sn=1052c393d678e529dffb7a2597d92520&chksm=cfbbd63cf3041047bf380708d449f8a1ac49361e295ddcfc555daf8d17cd2ba8542f95cfa32c&scene=126&sessionid=1724321524#rd

https://pubmed.ncbi.nlm.nih.gov/38785215/

Cancer Med

. 2024 May;13(10):e7295.

 doi: 10.1002/cam4.7295.

Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes

Lan Chen 1, Xi Yan 2, Ting Luo 2, Tinglun Tian 2, Ping He 2, Xiaorong Zhong 2

Affiliations collapse

Affiliations

• 1Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People's Republic of China.

• 2Department of Medical Oncology, Head and Neck Cancer Department, West China Hospital, Chengdu, Sichuan Province, People's Republic of China.

• PMID: 38785215

•  

• PMCID: PMC11117449

•  

• DOI: 10.1002/cam4.7295

中国知网 CNKI

文献检索与信息分析   艾立布林与乳腺癌

https://kns.cnki.net/kns8s/search?classid=WD0FTY92&kw=%E7%99%8C%E7%97%87%E5%85%8D%E7%96%AB%E7%96%97%E6%B3%95&korder=SU

• 艾立布林 (14)

•  晚期乳腺癌 (7)

•  临床研究 (3)

•  乳腺癌 (3)

•  转移性乳腺癌 (2)

•  晚期三阴性乳腺癌 (2)

•  临床疗效 (2)

•  乳腺癌患者 (1)

•  临床应用 (1)

•  特瑞普利单抗 (1)

http://www.pubmedplus.cn/P/SearchQuickResult?wd=0938ae1a-74e5-4eb4-909c-9dde028e63d3

• 主题词

• 记录数占%

01.	Breast Neoplasms	164 篇	100.000%
02.	Female	164 篇	100.000%
03.	Humans	164 篇	100.000%
04.	Prognosis	164 篇	100.000%
05.	Receptor, ErbB-2	164 篇	100.000%
06.	Receptors, Estrogen	164 篇	100.000%
07.	Receptors, Progesterone	164 篇	100.000%
08.	Middle Aged	138 篇	84.146%
09.	Adult	120 篇	73.171%
10.	Aged	112 篇	68.293%

http://www.pubmedplus.cn/P/SearchQuickResult?wd=53c36d2f-3512-436f-bd44-d8f89554a44d

• 主题词

• 记录数占%

01.	Female	75 篇	74.257%
02.	Humans	75 篇	74.257%
03.	Breast Neoplasms	67 篇	66.337%
04.	Antineoplastic Combined Chemotherapy Protocols	49 篇	48.515%
05.	Middle Aged	49 篇	48.515%
06.	Adult	45 篇	44.554%
07.	Receptor, ErbB-2	45 篇	44.554%
08.	Aged	44 篇	43.564%
09.	Capecitabine	44 篇	43.564%
10.	Furans	36 篇	35.644%

http://www.pubmedplus.cn/P/SearchQuickResult?wd=14a0b2e2-570c-48c0-9d6f-afa5ea2fac43

• 主题词

• 记录数占%

01.	Antineoplastic Agents	169 篇	100.000%
02.	Breast Neoplasms	169 篇	100.000%
03.	Humans	169 篇	100.000%
04.	Female	164 篇	97.041%
05.	Furans	145 篇	85.799%
06.	Ketones	145 篇	85.799%
07.	Middle Aged	78 篇	46.154%
08.	Aged	70 篇	41.420%
09.	Treatment Outcome	70 篇	41.420%
10.	Adult	64 篇	37.870%

http://www.pubmedplus.cn/P/SearchQuickResult?wd=62cff49e-0fc3-43ce-91d9-0d2daadb0e02

• 主题词

• 记录数占%

01.	Humans	72 篇	72.727%
02.	Furans	69 篇	69.697%
03.	Ketones	69 篇	69.697%
04.	Female	64 篇	64.646%
05.	Breast Neoplasms	58 篇	58.586%
06.	Middle Aged	34 篇	34.343%
07.	Antineoplastic Agents	32 篇	32.323%
08.	Adult	29 篇	29.293%
09.	Aged	29 篇	29.293%
10.	Antineoplastic Combined Chemotherapy Protocols	29 篇	29.293%

https://blog.sciencenet.cn/home.php?mod=spacecp&ac=blog&blogid=1447781&op=edit

转载本文请联系原作者获取授权，同时请注明本文来自许培扬科学网博客。
链接地址：https://blog.sciencenet.cn/blog-280034-1447781.html

上一篇：《自然》：禁食有促癌风险？
下一篇：中国知网 CNKI 文献检索与信息分析